Cepheid News

's stock had its "buy" rating reiterated by investment analysts at Canaccord Genuity in a note issued to investors on Thursday.

Cepheid Announces European Release of Xpert CT/NG and Xpert CT, Delivering Rapid Detection and Differentiation of Chlamydia and Gonorrhoeae SUNNYVALE, Calif., May 23, 2012 /PRNewswire/ -- Cepheid today announced that both Xpert CT/NG and Xpert CT have received CE marking, with shipments expected to begin immediately.

Amazon.com was upgraded today by Credit Suisse to outperform from neutral with a price target of $270, as recent investments made by the company should start to pay off and add to earnings soon.

Cepheid opened at 37.24 on Tuesday. Cepheid has a 52-week low of $29.53 and a 52-week high of $45.00. The company's market cap is $2.443 billion.

They currently have a $39.00 target price on the stock. Zacks ' analyst wrote, "Cepheid reported robust growth in revenues in the first quarter, which were in line with the Zacks Consensus Estimate.